[Report on notifications pursuant to Section 21 German Transfusion Act for 2007].
The present report contains the data collected in 2007, pursuant to Section 21 Transfusionsgesetz (German Transfusion Act), and an analysis of the supply situation over the past eight years. The recording of the data by online reporting is in the meantime well established and generally accepted. As in previous years, all blood donation centers located in Germany transmitted data on the collection, manufacture, import and export of blood components for transfusion, so that meaningful data are available. According to these data, a total of 6.7 million blood collections were performed in 2007. The number of whole blood donations was at the level of previous years, with 4.7 million, whereas the number of apheresis donations rose again, to 1.9 million. The portion of autologous blood collections accounts for only 1.1% and thus continues to decline. Since 2003, the number of red blood cell concentrates prepared has been a constant 4.5 million transfusion units. The decrease in the portion of decay of red blood cell concentrates on the user side is particularly good news. In 2000, it accounted for 5% and in 2007, it was just above 3%, referred to the total quantity of data reported as transfused and decayed. The manufacture of platelet concentrates rose from 366,000 to 480,000 transfusion units between 2003 and 2007. The production of therapeutic single plasmas also markedly increased in 2007 compared with previous years, accounting for 1.2 million transfusion units. In 2007, 2.2 million liters of plasma for fractionation were collected in Germany. This trend went hand in hand with the increasing number of apheresis donations that year. In addition, 1.0 million liters were imported, and, at the same time, 1.8 million liters were exported. The quantity available in Germany from a pure arithmetic point of view of 1.4 million liters was almost entirely allocated to basic fractionation, so that a sufficient plasma supply can be assumed. The assessment of the degree of self-sufficiency is made difficult because of the influence of imports and exports; however, the results show no deficit for plasma derivatives. Due to the fact that manufacturing capacities are still lacking in Germany, recombinant factors need to be imported in their entirety. Since 2003, Germany has by far been the leader in Europe with more than 20 liters of fractionation plasma collected per 1,000 inhabitants. Furthermore, regarding the manufacturing figures of red blood cell concentrates, platelet concentrates, and therapeutic single plasma, Germany is in the top third for all these products compared with other European countries. The manufacture of allogeneic stem cell products for hematopoietic reconstitution, obtained by apheresis, has continuously risen to 4,700 in the reporting year. A large portion of this, 1,810 transplants could be exported while only a small number, 179 preparations, had to be imported. The manufacture of autologous stem cell preparations from cord blood also rose drastically compared with 2006, to more than 10,000 in 2007. It must be emphasized that these products were entirely placed into stock; none were transplanted in the reporting year. The interest in the figures collected in compliance with Section 21, Transfusion Act remains high both in Germany and at the international level. Reliable data are available thanks to the evaluations of trends over years, above all on the availability of blood components for transfusion. In addition, the Paul Ehrlich Institute will continue to strive to meet the demands for high-quality information on the supply situation in the future.
Henseler
O
O
Paul-Ehrlich-Institut, Postfach, 63207 Langen. henol@pei.de
Heiden
M
M
Haschberger
B
B
Hesse
J
J
Seitz
R
R
D001779:Blood Coagulation Factors / Q000600:supply & distribution; D001781:Blood Component Removal / Q000706:statistics & numerical data; D016913:Blood Component Transfusion / Q000331:legislation & jurisprudence / Q000706:statistics & numerical data; D001782:Blood Donors / Q000331:legislation & jurisprudence* / Q000600:supply & distribution*; D001803:Blood Transfusion / Q000331:legislation & jurisprudence* / Q000706:statistics & numerical data*; D003431:Cross-Cultural Comparison; D003625:Data Collection / Q000331:legislation & jurisprudence*; D005858:Germany; D018380:Hematopoietic Stem Cell Transplantation / Q000331:legislation & jurisprudence / Q000706:statistics & numerical data; D006801:Humans; D011634:Public Health / Q000331:legislation & jurisprudence*; D011994:Recombinant Proteins / Q000600:supply & distribution; D014600:Utilization Review / Q000706:statistics & numerical data
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins